

Substitute for form 1449/PTO

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/009,473
Filing Date	November 8, 2001
First Named Inventor	Hagen, Michael
Group Art Unit	1648
Examiner Name	Emily M. Le
Attorney Docket Number	ACY33482

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If Known)	Kind Code (If Known)			
	1. 6,071,893			Graham et al.	06/06/2000	
	2. 6,514,503	B1		Gizuranson et al.	02-04-2003	
	3. 6,929,794	B1		Mills et al.	08-16-2005	
	4. 5,723,130			Hancock et al.	03-03-1998	
	5. 5,679,356			Bonnem et al.	10-21-1997	
	6. 5,976,539			Scott et al.	11-02-1999	
	7. 5,723,127			Scott et al.	03-03-1998	
	8. 5,980,911			Corner et al.	11-09-1999	
	9. 6,024,965			van Baalen et al.	02-15-2000	
	10. 6,113,918			Johnson et al.	09-05-2000	
	11. 6,096,313			Jager et al.	08-01-2000	
	12. 6,613,337	B1		Reed et al.	09-02-2003	
	13. 6,488,936	B1		Mishkin et al.	12-03-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	14. WO 96/10423				Noguchi et al.	04-11-1996		<input type="checkbox"/>
	15. WO 96/11019				Graham et al.	04-18-1996		<input type="checkbox"/>
	16. WO 98/50399				Johnson et al.	11-12-1998		<input type="checkbox"/>
	17. WO 00/60084				Vinals Y De Bassols et al.	10-12-2000		<input type="checkbox"/>
	18. WO 00/69456				Hagen	11-23-2000		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					T
		In re of Application of:	HAGEN, Michael	Group Art No.:	1645	Examiner:	
	19. USPTO FINAL OFFICE ACTION, MAILED MARCH 17, 2008	Application No.:	10/416,262	Filed:	May 8, 2003	For:	ADJUVANT COMBINATION FORMULATIONS
		Confirmation No.:	1455				
		Customer Number:	25291				
		Docket No.:	AM100449				
	20. USPTO FINAL OFFICE ACTION, MAILED OCTOBER 17, 2008	In re of Application of:	HAGEN, Michael	Group Art No.:	1645	Examiner:	Vanessa L. Ford
		Application No.:	11/544,056	Filed:	October 6, 2006	For:	ADJUVANT COMBINATION FORMULATIONS
		Confirmation No.:	7860				
		Customer Number:	25291				
		Docket No.:	AM100449 D1				

Examiner Signature

/Emily Le/

Date Considered

06/24/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO			Complete if Known		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/009,473	
(use as many sheets as necessary)			Filing Date	November 8, 2001	
Sheet	2	of	2	First Named Inventor	Hagen, Michael
				Group Art Unit	1648
				Examiner Name	Emily M. Le
				Attorney Docket Number	ACY33482

NON PATENT LITERATURE DOCUMENTS

Include name of the author(s), name of the document (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T

Examiner Initials*	Cite No		
	21.	Silla, S. et al., "Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL," 1999, European Cytokine Network, Vol. 10(2), pages 181-189	<input type="checkbox"/>
	22.	Hancock, G. E. et al., "QS-21 Synergizes with Recombinant Interleukin-12 to Create a Potent Adjuvant Formulation for the Fusion Protein of Respiratory Syncytial Virus," 2000, Viral Immunology, Vol. 13(4), pages 503-509	<input type="checkbox"/>
	23.	Weinberg, A. et al., "Recombinant Interleukin 2 As An Adjuvant for Vaccine-induced Protection," 1988 Jan 1, Journal of Immunology, Vol. 140(1), pages 294-299	<input type="checkbox"/>
	24.	Datta, S. K. et al, "Antigen-immunostimulatory oligo-nucleotide conjugates: mechanisms and applications," 2004 June, Immunological Reviews, Vol. 199, pages 217-226, Abstract Only	<input type="checkbox"/>
	25.	Schoenhaut, D. S. et al., "Cloning and Expression of Murine IL-12," 1992 Jun 1, Journal of Immunology, Vol. 148(11), pages 3433-3440	<input type="checkbox"/>
	26.	Singh, M. et al., "Advances in vaccine adjuvants," 1999 Nov, Nature Biotechnology, Vol. 17(11), pages 1075-1081	<input type="checkbox"/>
	27.	Vaslin, B. et al., "Induction of humoral and cellular immunity to simian immunodeficiency virus: what are the requirements for protection?" 1994, Vaccine, Vol. 12, pages 1132-1140	<input type="checkbox"/>

Examiner Signature	/Emily Le/	Date Considered	06/24/2009
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.